HNR1 Hannover Rueck SE

EQS-News: Hannover Re achieves Group net income of EUR 1.41 billion in 2022 and expects increase to at least EUR 1.7 billion in 2023

EQS-News: Hannover Rück SE / Key word(s): Annual Results
Hannover Re achieves Group net income of EUR 1.41 billion in 2022 and expects increase to at least EUR 1.7 billion in 2023

01.02.2023 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


Corporate news

Hannover Re achieves Group net income of EUR 1.41 billion in 2022 and expects increase to at least
EUR 1.7 billion in 2023 

  • Preliminary Group net income of EUR 1.41 billion in 2022
  • Gross premium increases by 12.7% in 2022 adjusted for exchange rate effects
  • Return on investment reaches 3.2% in the 2022 financial year
  • Return on equity reaches 14.1% in the 2022 financial year
  • Group net income of at least EUR 1.7 billion expected in 2023

Hannover, 1 February 2023: Hannover Re generated a Group net income of EUR 1.41 billion (previous year: EUR 1.23 billion) in the 2022 financial year based on preliminary, unaudited key figures, thus achieving the forecast specified in November 2022.

Gross written premium rose by 12.7% adjusted for exchange rate effects to EUR 33.3 billion (EUR 27.8 billion). The underwriting result in property and casualty reinsurance was characterised by high claims burdens. The result in life and health reinsurance was clearly above expectations and the previous year’s result, despite further losses associated with the pandemic. The return on investment from assets under own management reached 3.2% and was thus clearly above the target of more than 2.5%. Return on equity stood at 14.1%.

Guidance for 2023: Group net income under IFRS 17 of at least EUR 1.7 billion expected

Based on the continued favourable market environment, Hannover Re expects to grow its Group net income to at least EUR 1.7 billion for the 2023 financial year. The 2023 consolidated financial statements will be prepared using the new accounting standards (IFRS 17/9) for the first time. Reinsurance revenue is expected to grow by at least 5% at constant exchange rates and the return on investment from assets under own management should be at least 2.4%.

In order to take account of the growth in the property and casualty reinsurance portfolio and the increased loss expectation from natural catastrophes, Hannover Re has increased its net major-loss budget for 2023 to EUR 1.725 billion (EUR 1.4 billion).

“Thanks to our position as a profitable and sought-after business partner and in light of the attractive market environment, especially in property and casualty reinsurance, we again expect a satisfying Group net income for the current financial year,” said Jean-Jacques Henchoz, Chief Executive Officer of Hannover Re. “After the high burdens from major losses in the past years, we will stick to our conservative reserving policy in the current business year.”

As usual, all statements regarding future targets are subject to the premises that there are no unforeseen distortions on capital markets, that large loss expenditure remains within the expected value and the Covid-19 pandemic does not have any further significant impact on the result in life and health reinsurance. The ordinary dividend is expected to be at least stable compared to the previous year. This will be supplemented by a special dividend, provided the capitalisation exceeds the capital required for future growth and the profit target is achieved.

Hannover Re will publish its audited annual financial statements on 9 March 2023.

 

Hannover Re, with gross premium of more than EUR 33 billion, is the third-largest reinsurer in the world. It transacts all lines of property & casualty and life & health reinsurance and is present on all continents with more than 3,000 staff. Established in 1966, the Hannover Re Group today has a network of more than 170 subsidiaries, branches and representative offices worldwide. The Group's German business is written by the subsidiary E+S Rück. The rating agencies most relevant to the insurance industry have awarded both Hannover Re and E+S Rück outstanding financial strength ratings: Standard & Poor's AA- "Very Strong" and A.M. Best A+ "Superior".

Please note the disclaimer:



Contact

Media Relations: 
Oliver Suess
tel. 02 


Jessica Locker
tel. 99


Investor Relations:
Karl Steinle 
tel. 00 


Axel Bock 
tel. 36 




 



01.02.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: Hannover Rück SE
Karl-Wiechert-Allee 50
30625 Hannover
Germany
Phone: +49-(0)511-5604-1500
Fax: +49-(0)511-5604-1648
Internet: -re.com
ISIN: DE0008402215
WKN: 840 221
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange
EQS News ID: 1548191

 
End of News EQS News Service

1548191  01.02.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1548191&application_name=news&site_id=research_pool
EN
01/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hannover Rueck SE

Benoit Valleaux ... (+5)
  • Benoit Valleaux
  • Roland Pfaender
  • MBA
  • CFA
  • CCRA

Hannover Rueckversicherungs Ag: 1 director

A director at Hannover Rueckversicherungs Ag bought 400 shares at 239.400EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...

Bruno Cavalier ... (+4)
  • Bruno Cavalier
  • Hela Zarrouk
  • Oliver Metzger
  • Roy Külter
CON CONTINENTAL AKTIENGESELLSCHAFT
FME FRESENIUS MEDICAL CARE AG
LUFTHANSA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
FRA FRAPORT AG
TKA THYSSENKRUPP AG
WCH WACKER CHEMIE AG
DGE DIAGEO PLC
DB1 DEUTSCHE BOERSE AG
RNO RENAULT SA
ADS ADIDAS AG
G1A GEA GROUP AG
MC LVMH MOET HENNESSY LOUIS VUITTON SE
MTX MTU AERO ENGINES AG
CBK COMMERZBANK AG
RI PERNOD RICARD SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
DAI DAIMLER AG
RCO REMY COINTREAU SA
HNR1 HANNOVER RUECK SE
GBF BILFINGER SE
UTDI UNITED INTERNET AG
RHM RHEINMETALL AG
ALV ALLIANZ SE
LXS LANXESS AG
GXI GERRESHEIMER AG
EL ESSILORLUXOTTICA SA
KCO KLOECKNER & CO SE
BRBY BURBERRY GROUP PLC
MRK MERCK KGAA
KER KERING SA
VNA VONOVIA SE
EOAN E.ON SE
BOSS HUGO BOSS AG
SDF K+S AG
ZAL ZALANDO SE
G24 SCOUT24 AG
BAS BASF SE
RWE RWE AG
HEI HEIDELBERGCEMENT AG
BAYN BAYER AG
VOW3 VOLKSWAGEN AG PREF
HEN3 HENKEL AG & CO. KGAA PREF
DTE DEUTSCHE TELEKOM AG
TLX TALANX AG
SY1 SYMRISE AG
01913 PRADA S.P.A.
COFB COFINIMMO SA
FIE FIELMANN AG
DEZ DEUTZ AG
AIXA AIXTRON SE
NDA AURUBIS AG
KRN KRONES AG
NEM NEMETSCHEK SE
AED AEDIFICA SA
LEG LEG IMMOBILIEN AG
KGX KION GROUP AG
MONC MONCLER SPA
CPINV CARE PROPERTY INVEST SA
BNR BRENNTAG SE
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
RACE FERRARI NV
JUN3 JUNGHEINRICH AG PREF
FTG111 FLATEXDEGIRO AG
SIE SIEMENS AG
DUE DURR AG
SHL SIEMENS HEALTHINEERS AG
S92 SMA SOLAR TECHNOLOGY AG
JEN JENOPTIK AG
KBX KNORR-BREMSE AG
HAG HENSOLDT AG
CPR DAVIDE CAMPARI-MILANO N.V.
ENR SIEMENS ENERGY AG
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
STLA STELLANTIS N.V.
FPE3 FUCHS PETROLUB SE
BEAN BELIMO HOLDING AG
DTG DAIMLER TRUCK
ZGN ERMENEGILDO ZEGNA NV
STM STABILUS SE
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
TUI TUI AG
NCH2 THYSSENKRUPP NUCERA AG & CO.
SCHOTT PHARMA AG
R3NK RENK GROUP AG
QGEN QIAGEN N.V.
PFSE PFISTERER HOLDING SE
SHA SCHAEFFLER AG
TKMS TKMS AG & CO. KGAA

ResearchPool Subscriptions

Get the most out of your insights

Get in touch